AI-Designed vaccine takes on tough lung cancer
NCT ID NCT07285434
First seen Jan 09, 2026 · Last updated May 01, 2026 · Updated 19 times
Summary
This study tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and computer modeling to target their unique tumor. It is given alongside standard chemotherapy and immunotherapy to help the immune system fight the cancer more effectively. The trial aims to see if this combination shrinks tumors and helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenea Pharmaceuticals Ltd
Thessaloniki, Macedonia, 54627, Greece
Conditions
Explore the condition pages connected to this study.